Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal...
https://pubmed.ncbi.nlm.nih.gov/32085654/Actively Recruiting
Led by National Cheng-Kung University Hospital · Updated on 2026-04-20
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating treatments for gastrointestinal tumor bleeding, a serious condition affecting patients in Taiwan and elsewhere. This bleeding occurs due to fragile tumor blood vessels and abnormal tissue growth, making it difficult to control with standard endoscopic methods like injections, clips, or heat coagulation. The study also explores how tumor-derived exosomes containing VEGF and miR-21 may influence bleeding risk and tumor growth. The trial aims to improve bleeding control and understand the relationship between these exosomes and hemorrhage. The trial compares standard endoscopic treatment alone to standard treatment plus a spray of tranexamic acid and sucralfate powders applied directly to the bleeding tumor site. Both groups receive initial therapies such as epinephrine injection, clipping, and heat coagulation as decided by the endoscopist. The intervention group gets an additional 1.5 g of tranexamic acid powder and 3 g of sucralfate powder sprayed onto the bleeding site. After treatment, patients receive proton pump inhibitors intravenously for at least 72 hours. Immediate hemostasis is observed within minutes, and participants are monitored for bleeding recurrence over 30 days. Participants undergo endoscopic procedures, and blood and tumor tissue samples are collected to analyze tumor exosomes for VEGF and miR-21 levels. These measures help assess bleeding risk and the effectiveness of the treatment. The research team tracks immediate bleeding control and any rebleeding events within 30 days, along with other outcomes like the need for surgery or mortality. The study involves 60 patients and includes observation for safety and hospitalization duration, with the goal of advancing treatment options and bleeding risk prediction for gastrointestinal tumor bleeding.
CONDITIONS
Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial
H
Hsueh-Chien Chiang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cheng-Kung University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Treatment occurs during the endoscopy procedure and immediate observation period
Participants receive endoscopic treatment for upper gastrointestinal tumor bleeding. This includes conventional therapy such as epinephrine injection, clipping, and heat coagulation. Participants in the intervention group additionally receive topical application of sucralfate powder and tranexamic acid powder during the endoscopy. Immediate hemostasis is confirmed after treatment with 5 minutes of observation.
1 treatment visit (in-person)
Duration - 30 days
Participants are monitored for 30 days after treatment to assess rebleeding events, need for additional interventions such as surgery or embolization, mortality, and hospitalization duration.
Follow-up visits as needed within 30 days
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal...
https://pubmed.ncbi.nlm.nih.gov/32085654/Menghui Wang, Hongxin Shu, Xifu Cheng...
https://pubmed.ncbi.nlm.nih.gov/38240092/Hsueh-Chien Chiang, Po-Jun Chen, Er-Hsiang Yang...
https://pubmed.ncbi.nlm.nih.gov/39836033/Zhi Zheng, Yuhao Zhai, Xiaosheng Yan...
https://pubmed.ncbi.nlm.nih.gov/40083701/Hsueh-Chien Chiang, Po-Jun Chen, Er-Hsiang Yang...
https://pubmed.ncbi.nlm.nih.gov/37356632/Min Fu, Jianmei Gu, Pengcheng Jiang...
https://pubmed.ncbi.nlm.nih.gov/30876419/National Cheng-Kung University Hospital
Lead Sponsor